Biolase, Inc. (Form: 8-K)  

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     
Date of Report (Date of Earliest Event Reported):   May 6, 2016

Biolase, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)

     
Delaware 000-19627 87-0442441
_____________________
(State or other jurisdiction 		_____________
(Commission 		______________
(I.R.S. Employer
of incorporation) File Number) Identification No.)
      
4 Cromwell, Irvine, California   92618
_________________________________
(Address of principal executive offices) 		  ___________
(Zip Code)
     
Registrant’s telephone number, including area code:   949-361-1200

Not Applicable
______________________________________________
Former name or former address, if changed since last report

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Top of the Form

Item 5.07 Submission of Matters to a Vote of Security Holders.

On May 6, 2016, the 2016 Annual Meeting of Stockholders of Biolase, Inc. (the "Company") was held at the Company's headquarters, 4 Cromwell, Irvine, California. The following are the results of the voting on the proposals submitted to stockholders at the Annual Meeting.

1. Stockholders elected all of the Company's five nominees for director to serve a one-year term until the 2017 Annual Meeting of Stockholders and until their respective successors are elected and qualified, as set forth below:

Paul N. Clark
Votes For: 37,498,038
Votes Withheld: 248,304
Broker Non-votes: 13,127,587

Frederic H. Moll
Votes For: 37,480,545
Votes Withheld: 265,797
Broker Non-votes: 13,127,587

Harold C. Flynn, Jr.
Votes For: 37,503,877
Votes Withheld: 242,465
Broker Non-votes: 13,127,587

James R. Talevich
Votes For: 37,499,114
Votes Withheld: 247,228
Broker Non-votes: 13,127,587

Jonathan T. Lord
Votes For: 37,524,263
Votes Withheld: 222,079
Broker Non-votes: 13,127,587

2. Stockholders ratified the selection of BDO USA, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2016, as set forth below:

Votes For: 50,402,647
Votes Against: 235,137
Abstentions: 236,145
Broker Non-votes: 0

3. Stockholders approved the amendment to the 2002 Stock Incentive Plan, as set forth below:

Votes For: 36,197,415
Votes Against: 1,487,546
Abstentions: 61,381
Broker Non-votes: 13,127,587

4. Stockholders voted, on an advisory basis, to approve the compensation of the Company's named executive officers, as set forth below:

Votes For: 36,960,947
Votes Against: 660,484
Abstentions: 124,911
Broker Non-votes: 13,127,587





Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
    Biolase, Inc.
          
May 12, 2016   By:   David C. Dreyer
       
        Name: David C. Dreyer
        Title: Chief Financial Officer